WHO ICTRP trial
The role of hepcidin in predicting and conducting iron supplement for anemia in…
ChiCTR-DDD-17010847 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-DDD-17010847 |
|---|---|
| Public title | The role of hepcidin in predicting and conducting iron supplement for anemia in maintenance hemodialysis patients |
| Scientific title | The role of hepcidin in predicting and conducting iron supplement for anemia in maintenance hemodialysis patients |
| Primary sponsor | Xuzhou Central Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Diagnostic test |
| Phase | Diagnostic New Technique Clincal Study |
| Countries | China |
| Conditions | End stage renal disease |
| Interventions | Gold Standard:End stage renal disease (ESRD) patients, who are undergoing dialysis and have anemia. ;Index test:serum hepcidin |
| Registration date | Mar 12, 2017 |
| Target size | Target condition:160;Difficult condition:160 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: